DAFTAR PUSTAKA

Addicott, M. A., Baranger, D. A. A., Kozink, R. V., Smoski, M. J., Dichter, G. S., & McClernon, F. J. (2012). Smoking withdrawal is associated with increases in brain activation during decision making and reward anticipation: A preliminary study. *Psychopharmacology*, *2*, 563–573. https://doi.org/10.1007/s00213-011-2404-3

Adetunji, T. L., Acho, M. A., Samuel, V. O., Ohoro, C. R., & Ramulondi, M. (2024). Erythrina velutina Willd.: A review of its traditional uses, phytochemistry, pharmacology, and toxicology. *Journal of Ethnopharmacology*, *319*(P2), 117273. https://doi.org/10.1016/j.jep.2023.117273

Akers, A. T., Cooper, S. Y., Baumgard, Z. J., Casinelli, G. P., Avelar, A. J., & Henderson, B. J. (2020). Upregulation of NACHRS and changes in excitability on vta dopamine and gaba neurons correlates to changes in nicotine-reward-related behavior. *ENeuro*, *7*(5), 1–15. https://doi.org/10.1523/ENEURO.0189-20.2020

Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009). Mammalian nicotinic acetylcholine receptors: From structure to function. *Physiological Reviews*, *89*(1), 73–120. https://doi.org/10.1152/physrev.00015.2008

Ashok, A. H., Mizuno, Y., & Howe, O. D. (2019). *Tobacco smoking and dopaminergic function in humans : a meta-analysis of molecular imaging studies*. 1119–1129.

Azam, L., Winzer-Serhan, U. H., Chen, Y., & Leslie, F. M. (2002). Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *Journal of Comparative Neurology*, *444*(3), 260–274. https://doi.org/10.1002/cne.10138

Azmi, A. S., Rahim, N. A., Zahari, Z., & Salim, F. (2020). Cytotoxic activity of erythrina fusca lour. Leaf, twig and flower extracts. *Malaysian Journal of Analytical Sciences*, *24*(3), 313–319.

Baik, J. H. (2020). Stress and the dopaminergic reward system. *Experimental and Molecular Medicine*, *52*(12), 1879–1890. https://doi.org/10.1038/s12276-020-00532-4

Bedell, S., Wells, J., Liu, Q., & Breivogel, C. (2019). Vitexin as an active ingredient in passion flower with potential as an agent for nicotine cessation: vitexin antagonism of the expression of nicotine locomotor sensitization in rats. *Pharmaceutical Biology*, *57*(1), 8–12. https://doi.org/10.1080/13880209.2018.1561725

Beningera, R. J., & Gerdjikova, T. V. (2004). The Role of Signaling Molecules in Reward-Related Incentive Learning. *Neurotoxicity Research*, *6*(1), 91–104.

Benowitz, N. L. (2010). Nicotine Addiction. *N Engl J Med*, *362*(24), 2295–2393.

https://doi.org/10.1056/NEJMra0809890.Nicotine

Bhalsinge, R. R., Barde, A. A., Worlikar, P. S., Limaye, M. V., Dhole, M. P., & Tilak, A. V. (2017). Effect of nicotine on serotonin (5-HT) levels in brain of depressed rats. *International Journal of Basic & Clinical Pharmacology*, *6*(4), 938. https://doi.org/10.18203/2319-2003.ijbcp20171108

Bloem, B., Poorthuis, R. B., & Mansvelder, H. D. (2014). Cholinergic modulation of the medial prefrontal cortex: The role of nicotinic receptors in attention and regulation of neuronal activity. *Frontiers in Neural Circuits*, *8*(MAR), 1–16. https://doi.org/10.3389/fncir.2014.00017

Bordia, T., Hrachova, M., Chin, M., Mcintosh, J. M., & Quik, M. (2012). *Varenicline Is a Potent Partial Agonist at ␣ 6 ␤ 2 * Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum*. *342*(2), 327–334.

Bruijnzeel, A. W. (2012). Tobacco addiction and the dysregulation of brain stress systems. *Neuroscience and Biobehavioral Reviews*, *36*(5), 1418–1441. https://doi.org/10.1016/j.neubiorev.2012.02.015

Bruijnzeel, A. W. (2019). Nicotine, corticotropin-releasing factor, and anxiety-like behavior. In *Neuroscience of Nicotine: Mechanisms and Treatment*. Elsevier Inc. https://doi.org/10.1016/B978-0-12-813035-3.00020-4

Bruijnzeel, A. W., Ford, J., Rogers, J. A., Scheick, S., Ji, Y., & Alexander, J. C. (2012). Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. *Pharmacol Biochem Behav*, *101*(1), 62–68. https://doi.org/10.1016/j.pbb.2011.12.001.Blockade

Brynildsen, J. K., Najar, J., Hsu, L. M., Vaupel, D. B., Lu, H., Ross, T. J., Yang, Y., & Stein, E. A. (2016). A novel method to induce nicotine dependence by intermittent drug delivery using osmotic minipumps. *Pharmacology Biochemistry and Behavior*, *142*, 79–84. https://doi.org/10.1016/j.pbb.2015.12.010

Burke, M. V, Hays, T. J., & Ebbert, J. O. (2016). *Varenicline for smoking cessation : a narrative review of efficacy , adverse effects , use in at-risk populations , and adherence*. 435–441.

Cai, J., & Tong, Q. (2022). Anatomy and function of ventral tegmental area glutamate neurons. *Frontiers in Neural Circuits*, *16*(May). https://doi.org/10.3389/fncir.2022.867053

Carlson, A. B., & Kraus, G. P. (2019). Physiology, cholinergic receptors. *StatPearls*. http://www.ncbi.nlm.nih.gov/pubmed/30252390

Carvalho, A. C. C. S., Almeida, D. S., Melo, M. G. D., Cavalcanti, S. C. H., & Marçal, R. M. (2009). Evidence of the mechanism of action of *Erythrina velutina Willd* (Fabaceae) leaves aqueous extract. *Journal of Ethnopharmacology*, *122*(2), 374–378. https://doi.org/10.1016/j.jep.2008.12.019

Chae, Y., Yeom, M., Han, J.-H., Park, H.-J., Hahm, D.-H., Shim, I., Lee, H.-S., & Lee,

H. (2008). Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms. *Neuroscience Letters*, *430*(2), 98–102. https://doi.org/10.1016/j.neulet.2007.10.026

Chinta, S. J., & Andersen, J. K. (2005). Dopaminergic neurons. *International Journal of Biochemistry and Cell Biology*, *37*(5 SPEC. ISS.), 942–946. https://doi.org/10.1016/j.biocel.2004.09.009

Cho, S. Bin, Su, J., Kuo, S. I. C., Bucholz, K. K., Chan, G., Edenberg, H. J., McCutcheon, V. V., Schuckit, M. A., Kramer, J. R., & Dick, D. M. (2019). Positive and negative reinforcement are differentially associated with alcohol consumption as a function of alcohol dependence. *Psychology of Addictive Behaviors*, *33*(1), 58–68. https://doi.org/10.1037/adb0000436

Chu, H. B., Tan, Y. De, Li, Y. J., Cheng, B. Bin, Rao, B. Q., & Zhou, L. S. (2019). Anxiolytic and anti-depressant effects of hydroalcoholic extract from *Erythrina variegata* and its possible mechanism of action. *African Health Sciences*, *19*(3), 2526–2536. https://doi.org/10.4314/ahs.v19i3.28

Slawecki, C, & Ehlers, C. (2002). Lasting effects of adolescent nicotine exposure on the electroencephalogram, event related potentials, and locomotor activity in the rat. *Brain Research. Developmental Brain Research*, *138*(1), 15–25. https://doi.org/10.1016/s0165-3806(02)00455-8

Clarke, P. B. S., & Pert, A. (1985). Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. *Brain Research*, *348*(2), 355–358. https://doi.org/10.1016/0006-8993(85)90456-1

Clementson, S., Matheu, S. A., Rørsted, E. M., Pedersen, H., Jensen, A. A., Clausen, R. P., Vital, P., Glibstrup, E., Jessing, M., & Kristensen, J. L. (2021). *Erythrina* alkaloid analogues as nAChR antagonists-a flexible platform for leads in drug discovery. *Journal of Organic Chemistry*, *86*(12), 8248–8262. https://doi.org/10.1021/acs.joc.1c00707

Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., Shrikhande, A., Heym, J. H., Schaeffer, E., Rollema, H., Lu, Y., Mansbach, R. S., Chambers, L. K., Rovetti, C. C., Schulz, D. W., … Neill, B. T. O. (2005). *Varenicline : An r 4 2 Nicotinic Receptor Partial Agonist for Smoking Cessation*. *Chart 1*, 3474–3477.

Cohen, A., Treweek, J., Edwards, S., Leão, R. M., Schulteis, G., Koob, G. F., & George, O. (2013). Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. *Addiction Biology*, *20*(1), 56–68. https://doi.org/10.1111/adb.12077

Cohen, J. B., Sharp, S. D., & Liu, W. S. (1991). Structure of the agonist-binding site of the nicotinic acetylcholine receptor. [3H]acetylcholine mustard identifies residues in the cation-binding subsite. *Journal of Biological Chemistry*, *266*(34), 23354–23364. https://doi.org/10.1016/s0021-9258(18)54504-x

Compound summary Erythrinine. (n.d.). National Library of Medicine. Retrieved July 6, 2023, from https://pubchem.ncbi.nlm.nih.gov/compound/Erythrinine

Cools, R., & Arnsten, A. F. T. (2022). Neuromodulation of prefrontal cortex cognitive function in primates: the powerful roles of monoamines and acetylcholine. *Neuropsychopharmacology*, *47*(1), 309–328. https://doi.org/10.1038/s41386-021-01100-8

Cooper, S., Robison, A. J., & Mazei-Robison, M. S. (2017). Reward circuitry in addiction. *Neurotherapeutics*, *14*(3), 687–697. https://doi.org/10.1007/s13311-017-0525-z

Cosgrove, K. P., Batis, J., Bois, F., Maciejewski, P. K., Esterlis, I., Kloczynski, T., Stiklus, S., Krishnan-Sarin, S., O'Malley, S., Perry, E., Tamagnan, G., Seibyl, J. P., & Staley, J. K. (2009). B2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. *Archives of General Psychiatry*, *66*(6), 666–676. https://doi.org/10.1001/archgenpsychiatry.2009.41

Costa, J. P., De Oliveira, G. A. L., De Almeida, A. A. C., Islam, M. T., De Sousa, D. P., & De Freitas, R. M. (2014). Anxiolytic-like effects of phytol: Possible involvement of GABAergic transmission. *Brain Research*, *1547*, 34–42. https://doi.org/10.1016/j.brainres.2013.12.003

Crooks, P. A., Bardo, M. T., & Dwoskin, L. P. (2014). Nicotinic receptor antagonists as treatments for nicotine abuse. In *Advances in Pharmacology* (1st ed., Vol. 69). Elsevier Inc. https://doi.org/10.1016/B978-0-12-420118-7.00013-5

Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. *Psychopharmacology*, *168*(3), 347–358. https://doi.org/10.1007/s00213-003-1445-7

D'souza, M. S., & Markou, A. (2013). The "Stop" and "Go" of nicotine dependence: Role of GABA and glutamate. *Cold Spring Harbor Perspectives in Medicine*, *3*(6). https://doi.org/10.1101/cshperspect.a012146

D'Souza, M. S., & Markou, A. (2011). Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. *Addiction Science & Clinical Practice*, *6*(1), 4–16.

D'Souza, M. S., & Markou, A. (2011). *4 • A D D I C T I O N S C I E N C E & C L I N I C A L P R A C T I C E-J U L Y 2 0 1 1 Neuronal Mechanisms Underlying Development of Nicotine Dependence: Implications for Novel Smoking-Cessation Treatments*. *July*, 4–16.

Dai, X., Gakidou, E., & Lopez, A. D. (2022). Evolution of the global smoking epidemic over the past half century: Strengthening the evidence base for policy action. *Tobacco Control*, *31*(2), 129–137. https://doi.org/10.1136/tobaccocontrol-2021-056535

Dajas-Bailador, F., & Wonnacott, S. (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signalling. *Trends in Pharmacological Sciences*, *25*(6), 317–324. https://doi.org/10.1016/j.tips.2004.04.006

Dani, J. A., & De Biasi, M. (2001). Cellular mechanisms of nicotine addiction. *Pharmacology Biochemistry and Behavior*, *70*(4), 439–446. https://doi.org/10.1016/S0091-3057(01)00652-9

Dantas, M. C., De Oliveira, F. S., Bandeira, S. M., Batista, J. S., Silva, C. D., Alves, P. B., Antoniolli, A. R., & Marchioro, M. (2004). Central nervous system effects of the crude extract of *Erythrina velutina* on rodents. *Journal of Ethnopharmacology*, *94*(1), 129–133. https://doi.org/10.1016/j.jep.2004.05.007

De Kloet, S. F., Mansvelder, H. D., & De Vries, T. J. (2015). Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. *Biochemical Pharmacology*, *97*(4), 425–438. https://doi.org/10.1016/j.bcp.2015.07.014

de Oliveira, D. D., da Silva, C. P., Iglesias, B. B., & Beleboni, R. O. (2020). Vitexin possesses anticonvulsant and anxiolytic-like effects in murine animal models. *Frontiers in Pharmacology*, *11*(August), 1–9. https://doi.org/10.3389/fphar.2020.01181

de Oliveira, D. R., Zamberlam, C. R., Gaiardo, R. B., Rêgo, G. M., Cerutti, J. M., Cavalheiro, A. J., & Cerutti, S. M. (2014). Flavones from *Erythrina falcata* are modulators of fear memory. *BMC Complementary and Alternative Medicine*, *14*(1), 1–17. https://doi.org/10.1186/1472-6882-14-288

Decker, M. W., Anderson, D. J., Brioni, J. D., Donnelly-Roberts, D. L., Kang, C. H., O'Neill, A. B., Piattoni-Kaplan, M., Swanson, S., & Sullivan, J. P. (1995). Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. *European Journal of Pharmacology*, *280*(1), 79–89. https://doi.org/10.1016/0014-2999(95)00191-M

Devi, R., Barman, D., Sinha, S., Hazarika, S., & Das, S. (2020). Nicotine replacement therapy: A friend or foe. *Journal of Family Medicine and Primary Care*, *9*(6), 2615. https://doi.org/10.4103/jfmpc.jfmpc_313_20

DH, M., JR, L., Newlin-Maultsby, P., LK, R., JG, L., VA, C., JS, C., & OB, W. (1992). Rodent model of nicotine abstinence syndrome. *Pharmacology, Biochemistry, and Behavior*, *43*(3), 779–784. https://doi.org/10.1016/0091-3057(92)90408-8

Di Pasquale, G., Dicembrini, I., Raimondi, L., Pagano, C., Egan, J. M., Cozzi, A., Cinci, L., Loreto, A., Manni, M. E., Berretti, S., Morelli, A., Zheng, C., Michael, D. G., Maggi, M., Vettor, R., Chiorini, J. A., Mannucci, E., & Rotella, C. M. (2012). Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. *PloS One*, *7*(7), e40074. https://doi.org/10.1371/journal.pone.0040074

Doura, M. B., Gold, A. B., Keller, A. B., & Perry, D. C. (2008). Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the

response of these subtypes to chronic nicotine exposure. *Brain Research*, *1215*, 40–52. https://doi.org/10.1016/j.brainres.2008.03.056

E. Sher, Y. Chen, T.J.W. Sharples, L.M. Broad, G. Benedetti, R. Zwart, G.I. McPhie, K.H. Pearson, T. Baldwinson, & G. De Filippi. (2005). Physiological roles of neuronal nicotinic receptors subtypes: New insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. *Current Topics in Medicinal Chemistry*, *4*(3), 283–297. https://doi.org/10.2174/1568026043451393

Emmanuel, T., Dairou, H., Jacqueline, N., Gisèle, N., Abel, Y. G., Esther, N., Elisabeth, N. B., & Joseph, M. T. (2015). Study of the anti-anxiety properties of the phaseollidin, an isoflavonoid isolated from *Erythrina droogmansiana* (Leguminosae). *World Journal of Pharmaceutical Science*, *3*(9), 1763–1775.

Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998). Dramatic decreases in brain reward function during nicotine withdrawal. *Nature*, *393*(6680), 76–79. https://doi.org/10.1038/30001

Everitt, B. J., & Robbins, T. W. (2016). Drug Addiction: Updating actions to habits to compulsions ten years on barry. *Annual Review of Psychology*, *July 2015*, 1–28. https://doi.org/10.1146/annurev-psych-122414-033457

Faggion, S. A., Cunha, A. O. S., Fachim, H. A., Gavin, A. S., dos Santos, W. F., Pereira, A. M. S., & Beleboni, R. O. (2011). Anticonvulsant profile of the alkaloids *(+)-erythravine* and *(+)-11-α-hydroxy-erythravine* isolated from the flowers of *Erythrina mulungu Mart* ex Benth (Leguminosae-Papilionaceae). *Epilepsy and Behavior*, *20*(3), 441–446. https://doi.org/10.1016/j.yebeh.2010.12.037

Fahmy, N., Alsayed, E., El-Shazly, M., & Singab, A. N. (2019). Alkaloids of genus *Erythrina* : An updated review. *Natural Product Research*, *34*, 1–22. https://doi.org/10.1080/14786419.2018.1564300

Fahmy, N. M., Al-Sayed, E., El-Shazly, M., & Nasser Singab, A. (2020). Alkaloids of genus *Erythrina*: An updated review. *Natural Product Research*, *34*(13), 1891–1912. https://doi.org/10.1080/14786419.2018.1564300

Fahmy, N. M., Al-Sayed, E., El-Shazly, M., & Singab, A. N. (2018). Comprehensive review on flavonoids biological activities of *Erythrina* plant species. *Industrial Crops and Products*, *123*(May), 500–538. https://doi.org/10.1016/j.indcrop.2018.06.028

Fields, H. L., Hjelmstad, G. O., Margolis, E. B., & Nicola, S. M. (2007). Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. *Annual Review of Neuroscience*, *30*, 289–316. https://doi.org/10.1146/annurev.neuro.30.051606.094341

Filip, M., Smaga, I., & Przegaliński, E. (2020). The role of serotonin in nicotine abuse and addiction. *Handbook of Behavioral Neuroscience*, *31*, 829–841. https://doi.org/10.1016/B978-0-444-64125-0.00042-6

Flausino, O. A., Pereira, A. M., Bolzani, V. D. S., & Nunes-De-Souza, R. L. (2007). Effects of erythrinian alkaloids isolated from *Erythrina mulungu* (Papilionaceae) in mice submitted to animal models of anxiety. *Biological and Pharmaceutical Bulletin*, *30*(2), 375–378. https://doi.org/10.1248/bpb.30.375

Gaimarri, A., Moretti, M., Riganti, L., Zanardi, A., Clementi, F., & Gotti, C. (2007). Regulation of neuronal nicotinic receptor traffic and expression. *Brain Research Reviews*, *55*(1), 134–143. https://doi.org/10.1016/j.brainresrev.2007.02.005

Garcia-Fernandez, G., Krotter, A., Gonz, A., García-fern, G., & Secades-villa, R. (2023). Effectiveness of including weight management in smoking cessation treatments: A meta-analysis of behavioral interventions. *Addictive Behaviors*, *140*(January). https://doi.org/10.1016/j.addbeh.2023.107606

Geisler, S., & Trimble, M. (2008). The lateral habenula: No longer neglected. *CNS Spectrums*, *13*(6), 484–489. https://doi.org/10.1017/S1092852900016710

Geisler, S., & Wise, R. A. (2008). Functional implications of glutamatergic projections to the ventral tegmental area. *Reviews in the Neurosciences*, *19*(4–5), 227–244. https://doi.org/10.1515/REVNEURO.2008.19.4-5.227

Gelfuso, E. A., Reis, S. L., Aguiar, D. S. R., Faggion, S. A., Gomes, F. M. M., Galan, D. T., Peigneur, S., Pereira, A. M. S., Mortari, M. R., Cunha, A. O. S., Tytgat, J., & Beleboni, R. O. (2020). New insights in the mode of action of *(+)-erythravine* and *(+)-11α-hydroxy-erythravine* alkaloids. *European Journal of Pharmacology*, *885*(July). https://doi.org/10.1016/j.ejphar.2020.173390

George, O., Ghozland, S., Azar, M. R., Cottone, P., Zorrilla, E. P., Parsons, L. H., O'Dell, L. E., Richardson, H. N., & Koob, G. F. (2007). CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. *Proceedings of the National Academy of Sciences of the United States of America*, *104*(43), 17198–17203. https://doi.org/10.1073/pnas.0707585104

George, O., Grieder, T. E., Cole, M., & Koob, G. F. (2010). Exposure to chronic intermittent nicotine vapor induces nicotine dependence. *Pharmacology, Biochemistry, and Behavior*, *96*(1), 104–107. https://doi.org/10.1016/j.pbb.2010.04.013

George, O., & Koob, G. F. (2017). Overview of nicotine withdrawal and negative reinforcement (Preclinical). In *Negative Affective States and Cognitive Impairments in Nicotine Dependence*. Elsevier Inc. https://doi.org/10.1016/B978-0-12-802574-1.00001-6

George, O., Lloyd, A., Torrey, N., Road, P., Jolla, L., Carroll, F. I., & Koob, G. F. (2024). *Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration*. *213*(4), 715–722. https://doi.org/10.1007/s00213-010-2024-3.Varenicline

Goldstein, R. Z., & Volkow, N. D. (2012). Dysfunction of the prefrontal cortex in

addiction: neuroimaging findings and clinical implications. *Nat Rev Neurosci*, *12*(11), 652–669. https://doi.org/10.1038/nrn3119.Dysfunction

Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., Watsky, E. J., Gong, J., Williams, K. E., & Reeves, K. R. (2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. *Jama*, *296*(1), 47–55. https://doi.org/10.1001/jama.296.1.47

Govind, A. P., Vezina, P., & Green, W. N. (2009). Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine addiction. *Biochemical Pharmacology*, *78*(7), 756–765. https://doi.org/10.1016/j.bcp.2009.06.011

Govind, A. P., Walsh, H., & Green, W. N. (2012). Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. *32*(6), 2227–2238. https://doi.org/10.1523/JNEUROSCI.5438-11.2012

Gozen, O., Aypar, B., Ozturk Bintepe, M., Tuzcu, F., Balkan, B., Koylu, E. O., Kanit, L., & Keser, A. (2024). Chronic nicotine consumption and withdrawal regulate melanocortin receptor, CRF, and CRF receptor mRNA levels in the rat brain. *Brain Sciences*, *14*(1). https://doi.org/10.3390/brainsci14010063

Grabus, S. D., Carroll, F. I., & Damaj, M. I. (2012). Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse. *Nicotine and Tobacco Research*, *14*(11), 1356–1361. https://doi.org/10.1093/ntr/nts088

Grieder, T. A., Herman, M. A., Contet, C., Tan, L. A., Vargas-Perez, H., Cohen, A., Chwalek, M., Maal-Bared, G., Freiling, J., Schlosburg, J. E., Clarke, L., Crawford, E., Koebel, P., Canonigo, V., Sanna, P., Tapper, A., Roberto, M., Kieffer, B. L., Sawchenko, P. E., … George, O. (2014). CRF neurons in the ventral tegmental area control the aversive effects of nicotine withdrawal and promote escalation of nicotine intake. *Nature Neuroscience*, *17*(12), 1751–1758. https://doi.org/10.1038/nn.3872.CRF

Grillner, P., & Svensson, T. H. (2000). Nicotine-induced excitation of midbrain dopamine neurons in vitro involves ionotropic glutamate receptor activation. *Synapse*, *38*(1), 1–9. https://doi.org/10.1002/1098-2396(200010)38:1<1::AID-SYN1>3.0.CO;2-A

Grima, L. L., Walton, M. E., & Husain, M. (2022). Nucleus accumbens D1-receptors regulate and focus transitions to reward-seeking action. *March*. https://doi.org/10.1038/s41386-022-01312-6

Gupta, R., Bharat, A., Dhiman, U., & Sharma, A. (2019). Nicotine replacement therapy: A smoking cessation aid… an overview. *International Journal of Oral Health Dentistry*, *5*(2), 69–75. https://doi.org/10.18231/j.ijohd.2019.017

Haass-Koffler, C. L., & Bartlett, S. E. (2012). Stress and addiction: Contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. *Frontiers in*

Molecular Neuroscience, *5*(AUG 2012), 1–31. https://doi.org/10.3389/fnmol.2012.00091

Hajiasgharzadeh, K., Naghipour, B., & Shahabi, P. (2023). Review article: The role of microRNAs in nicotine signaling. *EXCLI Journal*, *22*, 433–450.

Halder, N., & Lal, G. (2021). Cholinergic system and its therapeutic importance in inflammation and autoimmunity. *Frontiers in Immunology*, *12*(April). https://doi.org/10.3389/fimmu.2021.660342

Hanrahan, J. R., Chebib, M., & Johnston, G. A. R. (2011). Flavonoid modulation of GABA A receptors. *British Journal of Pharmacology*, *163*(2), 234–245. https://doi.org/10.1111/j.1476-5381.2011.01228.x

Henderson, B. J., & Lester, H. (2016). *Inside-out neuropharmacology of nicotinic drugs*. *96*(0 0), 178–193. https://doi.org/10.1016/j.neuropharm.2015.01.022.Inside-out

Henderson, B. J., Wall, T. R., Henley, B. M., Kim, C. H., Mckinney, S., & Lester, H. A. (2017). Menthol enhances nicotine reward-related behavior by potentiating nicotine-induced changes in nachr function, nachr upregulation, and DA neuron excitability. *Neuropsychopharmacology*, *42*(12), 2285–2291. https://doi.org/10.1038/npp.2017.72

Hendrickson, L. M., Guildford, M. J., & Tapper, A. R. (2013). Neuronal nicotinic acetylcholine receptors: Common molecular substrates of nicotine and alcohol dependence. *Frontiers in Psychiatry*, *4*(APR), 1–16. https://doi.org/10.3389/fpsyt.2013.00029

Hinds, J. A., & Sanchez, E. R. (2022). The role of the Hypothalamus–Pituitary–Adrenal (HPA) Axis in test-induced anxiety: Assessments, physiological responses, and molecular details. *Stresses*, *2*(1), 146–155. https://doi.org/10.3390/stresses2010011

Hogan, E. M., Casserly, A. P., Scofield, M. D., Mou, Z., Zhao-shea, R., Johnson, C. W., Tapper, A. R., & Gardner, P. D. (2014). miRNAome analysis of the mammalian neuronal nicotinic acetylcholine receptor gene family. *RNA*, 1890–1899. https://doi.org/10.1261/rna.034066.112.1890

Hughes, J. R., & Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. *Archives of General Psychiatry*, *43*(3), 289–294. https://doi.org/10.1001/archpsyc.1986.01800030107013

Hughes, J. R., Stead, L. F., & Lancaster, T. (2000). Anxiolytics for smoking cessation. *Cochrane Database of Systematic Reviews*, *2011*(8). https://doi.org/10.1002/14651858.CD002849

Hughes, J., Stead, L., & Lancaster, T. (2003). Antidepressants for smoking cessation. *Cochrane Database of Systematic Reviews*, *5*. https://doi.org/10.1002/14651858.cd000031

Hurley, R. A., Hayman, L. A., & Taber, K. H. (2009). Windows to the brain. *Journal of Neuropsychiatry and Clinical Neurosciences*, *21*(1), 1–4. https://doi.org/10.4088/jcp.10bk06693whi

Hussain, M. M., Tuhin, M. T. H., Akter, F., & Rashid, M. A. (2016). Constituents of *Erythrina* - a potential source of secondary metabolities: A review. *Bangladesh Pharmaceutical Journal*, *19*(2), 237–253. https://doi.org/10.3329/bpj.v19i2.29287

Iemolo, A., Blasio, A., St Cyr, S. A., Jiang, F., Rice, K. C., Sabino, V., & Cottone, P. (2013). CRF-CRF 1 receptor system in the central and basolateral nuclei of the amygdala differentially mediates excessive eating of palatable food. *Neuropsychopharmacology*, *38*(12), 2456–2466. https://doi.org/10.1038/npp.2013.147

Igari, M., Alexander, J. C., Ji, Y., Qi, X., Papke, R. L., & Bruijnzeel, A. W. (2014). Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. *Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology*, *39*(2), 455–465. https://doi.org/10.1038/npp.2013.216

Ikemoto, S., Glazier, B. S., Murphy, J. M., & Mcbride, W. J. (1997). Role of dopamine D 1 and D 2 receptors in the nucleus accumbens in mediating reward. *17*(21), 8580–8587.

Islam, M. T., Ali, E. S., Uddin, S. J., Shaw, S., Islam, M. A., Ahmed, M. I., Chandra Shill, M., Karmakar, U. K., Yarla, N. S., Khan, I. N., Billah, M. M., Pieczynska, M. D., Zengin, G., Malainer, C., Nicoletti, F., Gulei, D., Berindan-Neagoe, I., Apostolov, A., Banach, M., … Atanasov, A. G. (2018). Phytol: A review of biomedical activities. *Food and Chemical Toxicology*, *121*(August), 82–94. https://doi.org/10.1016/j.fct.2018.08.032

Isola, R., Vogelsberg, V., Wemlinger, T. A., Neff, N. H., & Hadjiconstantinou, M. (1999). Nicotine abstinence in the mouse. *Brain Research*, *850*(1–2), 189–196. https://doi.org/10.1016/S0006-8993(99)02131-9

Iturriaga-Vásquez, P., Carbone, A., García-Beltrán, O., Livingstone, P. D., Biggin, P. C., Cassels, B. K., Wonnacott, S., Zapata-Torres, G., & Bermudez, I. (2010). Molecular determinants for competitive inhibition of α4β2 nicotinic acetylcholine receptors. *Molecular Pharmacology*, *78*(3), 366–375. https://doi.org/10.1124/mol.110.065490

Jäger, A. K., & Saaby, L. (2011). Flavonoids and the CNS. *Molecules*, *16*, 1471–1485. https://doi.org/10.3390/molecules16021471

Jensen, A. A., Frølund, B., Liljefors, T., & Krogsgaard-Larsen, P. (2005). Neuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirations. *Journal of Medicinal Chemistry*, *48*(15), 4705–4745. https://doi.org/10.1021/jm040219e

Jiloha, R. C. (2014). Pharmacotherapy of smoking cessation. *Indian Journal of*

Psychiatry, *56*(1), 87–95. https://doi.org/10.4103/0019-5545.124726

Juárez Olguín, H., Calderón Guzmán, D., Hernández García, E., & Barragán Mejía, G. (2016). The role of dopamine and its dysfunction as a consequence of oxidative stress. *Oxidative Medicine and Cellular Longevity*, *2016*. https://doi.org/10.1155/2016/9730467

Kamens, H. M., Jimena ANdersen, & Mariana R. Piccioto. (2010). The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice. *Alcohol Clin Exp Res*, *34*(12), 2053–2060. https://doi.org/10.1016/j.earlhumdev.2006.05.022

Kaushal, A., Sharma, M., Navneet, & Sharma, M. (2020). Ethnomedicinal, phytochemical, therapeutic and pharmacological review of the genus *Erythrina*. *International Journal of Botany Studies*, *5*(6), 642–648. www.botanyjournals.com

Kim, R. K., Truby, N. L., Silva, G. M., Picone, J. A., Miller, C. S., Baldwin, A. N., & Neve, R. L. (2024). Histone H1x in mouse ventral hippocampus associates with , but does not cause behavioral adaptations to stress. *Translational Psychiatry*, *May*, 1–10. https://doi.org/10.1038/s41398-024-02931-x

Klawonn, A. M., & Malenka, R. C. (2018). Nucleus accumbens modulation in reward and aversion. *Cold Spring Harbor Symposia on Quantitative Biology*, *83*, 119–129. https://doi.org/10.1101/sqb.2018.83.037457

Koob, G. F. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. *Brain Research*, *1314*, 3–14. https://doi.org/10.1016/j.brainres.2009.11.008

Koob, G. F. (2015). The dark side of emotion : the addiction perspective. *European Journal of Pharmacology*, *15*(753), 73–87. https://doi.org/10.1016/j.ejphar.2014.11.044.The

Koob, G. F., & Le Moal, M. (2008). Addiction and the brain antireward system. *Annual Review of Psychology*, *59*, 29–53. https://doi.org/10.1146/annurev.psych.59.103006.093548

Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. *The Lancet Psychiatry*, *3*(8), 760–773. https://doi.org/10.1016/S2215-0366(16)00104-8

Kretz, O., Reichardt, H. M., Schütz, G., & Bock, R. (1999). Corticotropin-releasing hormone expression is the major target for glucocorticoid feedback-control at the hypothalamic level. *Brain Research*, *818*(2), 488–491. https://doi.org/10.1016/S0006-8993(98)01277-3

Kumar, M. (2020). Anxiolytic activity of methanolic extract of *Erythrina variegata Linn.* leaves in Wistar rats. *Research in Pharmacy and Health Sciences*, *05*(04), 205–208. https://doi.org/10.32463/rphs.2020.v06i01.03

Lancaster, T., & Stead, L. F. (1998). Mecamylamine (a nicotine antagonist) for smoking cessation. *Cochrane Database of Systematic Reviews*, *2017*(12). https://doi.org/10.1002/14651858.CD001009

LE, O., AW, B., Ghozland, S., Markou, A., & GF, K. (2004). Nicotine withdrawal in adolescent and adult rats. In *Annals of the New York Academy of Sciences* (Vol. 1021, pp. 167–174). https://doi.org/10.1196/annals.1308.022

Lee, C. (2003). Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants. *Pharmacology and Therapeutics*, *98*(2), 143–169. https://doi.org/10.1016/S0163-7258(03)00030-5

Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., Chen, L., Chen, L., Chen, T. M., Chin, M. C., Chong, J., Crook, B. E., Czaplinska, A., Dang, C. N., Datta, S., … Jones, A. R. (2007). Genome-wide atlas of gene expression in the adult mouse brain. *Nature*, *445*(7124), 168–176. https://doi.org/10.1038/nature05453

Leslie, F. M. (2020). Unique, long-term effects of nicotine on adolescent brain Frances. 1–24. https://doi.org/10.1016/j.pbb.2020.173010.Unique

Li, N., & Jasanoff, A. (2020). Local and global consequences of reward-evoked striatal dopamine release. *Nature*, *580*(7802), 239–244. https://doi.org/10.1038/s41586-020-2158-3

Liechti, M. E., & Markou, A. (2008). Role of the glutamatergic system in nicotine dependence. *CNS Drugs*, *22*(9), 705–724. https://doi.org/10.2165/00023210-200822090-00001

Lindson, N., Butler, A. R., McRobbie, H., Bullen, C., Hajek, P., Begh, R., Theodoulou, A., Notley, C., Rigotti, N. A., Turner, T., Livingstone-Banks, J., Morris, T., & Hartmann-Boyce, J. (2024). Electronic cigarettes for smoking cessation. *Cochrane Database of Systematic Reviews*, *2024*(1). https://doi.org/10.1002/14651858.CD010216.pub8

Liu, C. Y., Deng, P., Wang, B., Liu, A. H., Wang, M. G., Li, S. W., Chen, L. L., & Mao, S. C. (2023). Coumaronochromones, flavanones, and isoflavones from the twigs and leaves of *Erythrina subumbrans* inhibit PTP1B and nitric oxide production. *Phytochemistry*, *206*(December 2022), 113550. https://doi.org/10.1016/j.phytochem.2022.113550

Liu, L., Hendrickson, L. M., Guildford, M. J., Zhao-Shea, R., Gardner, P. D., & Tapper, A. R. (2013). Nicotinic acetylcholine receptors containing the α4 subunit modulate alcohol reward. *Biological Psychiatry*, *73*(8), 738–746. https://doi.org/10.1016/j.biopsych.2012.09.019

Logrip, M. D., Koob, G. F., & Zorrilla, E. P. (2011). Role of Corticotropin-Releasing Factor in drug addiction: Potential for Pharmacological Intervention Marian. *CNS & Neurological Disorders Drug Targets*, *25*(4), 271–287. https://doi.org/10.2165/11587790-000000000-00000.Role

Lovenberg, T. W., Liaw, C. W., Grigoriadis, D. E., Clevenger, W., Chalmers, D. T., De Souza, E. B., & Oltersdorf, T. (1995). Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. *Proceedings of the National Academy of Sciences of the United States of America*, *92*(3), 836–840. https://doi.org/10.1073/pnas.92.3.836

Luo, S. X., & Huang, E. J. (2016). Dopaminergic neurons and brain reward pathways: From neurogenesis to circuit assembly. *American Journal of Pathology*, *186*(3), 478–488. https://doi.org/10.1016/j.ajpath.2015.09.023

Lutfy, K., Aimiuwu, O., Mangubat, M., Shin, C. S., Nerio, N., Gomez, R., Liu, Y., & Friedman, T. C. (2012). Nicotine stimulates secretion of corticosterone via both CRH and AVP receptors. *Journal of Neurochemistry*, *120*(6), 1108–1116. https://doi.org/10.1111/j.1471-4159.2011.07633.x

Maj, M., Turchan, J., Śmiałowska, M., & Przewłocka, B. (2003). Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. *Neuropeptides*, *37*(2), 105–110. https://doi.org/10.1016/S0143-4179(03)00021-0

Mannucci, C., Navarra, M., Calzavara, E., Caputi, A. P., & Calapai, G. (2012). Serotonin involvement in *Rhodiola rosea* attenuation of nicotine withdrawal signs in rats. *Phytomedicine*, *19*(12), 1117–1124. https://doi.org/10.1016/j.phymed.2012.07.001

Mansbach, R. S., Chambers, L. K., & Rovetti, C. C. (2000). Effects of the competitive nicotinic antagonist *erysodine* on behavior occasioned or maintained by nicotine: Comparison with mecamylamine. *Psychopharmacology*, *148*(3), 234–242. https://doi.org/10.1007/s002130050047

Mansvelder, H. D., & Mcgehee, D. S. (2000). Long-term potentiation of excitatory inputs to brain reward areas by nicotine VTA neuron activity and ultimately DA release in the NAcc (Kalivas et al. *Neuron*, *27*, 349–357.

Mansvelder, H. D., & McGehee, D. S. (2002). Cellular and synaptic mechanisms of nicotine addiction. *Journal of Neurobiology*, *53*(4), 606–617. https://doi.org/10.1002/neu.10148

Marder, M. (2012). Flavonoids as GABAA receptor ligands: the whole story? *Journal of Experimental Pharmacology*, 9. https://doi.org/10.2147/jep.s23105

Markou, A. (2008). Neurobiology of nicotine dependence. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *363*(1507), 3159–3168. https://doi.org/10.1098/rstb.2008.0095

Martins, J., & Brijesh, S. (2020). Anti-depressant activity of *Erythrina variegata* bark extract and regulation of monoamine oxidase activities in mice. In *Journal of Ethnopharmacology* (Vol. 248). Elsevier B.V. https://doi.org/10.1016/j.jep.2019.112280

Matera, C., Papotto, C., Dallanoce, C., & De Amici, M. (2023). Advances in small

molecule selective ligands for heteromeric nicotinic acetylcholine receptors. *Pharmacological Research*, *194*(June), 106813. https://doi.org/10.1016/j.phrs.2023.106813

Matsuura, H. N., & Fett-Neto, A. G. (2015). Plant alkaloids: Main features, toxicity, and mechanisms of action. *Plant Toxins*, *July*, 1–15. https://doi.org/10.1007/978-94-007-6728-7_2-1

Matta, S. G., Balfour, D. J., Benowitz, N. L., Boyd, R. T., Buccafusco, J. J., Caggiula, A. R., Craig, C. R., Collins, A. C., Damaj, M. I., Donny, E. C., Gardiner, P. S., Grady, S. R., Heberlein, U., Leonard, S. S., Levin, E. D., Lukas, R. J., Markou, A., Marks, M. J., McCallum, S. E., … Zirger, J. M. (2007). Guidelines on nicotine dose selection for in vivo research. *Psychopharmacology*, *190*(3), 269–319. https://doi.org/10.1007/s00213-006-0441-0

Melroy-Greif, W. E., Stitzel, J. A., & Ehringer, M. A. (2016). Nicotinic acetylcholine receptors: Upregulation, age-related effects and associations with drug use. *Genes, Brain and Behavior*, *15*(1), 89–107. https://doi.org/10.1111/gbb.12251

Melroy-greif, W. E., Stitzel, J. A., Ehringer, M. A., Neuroscience, C., & Jolla, L. (2016). *Nicotinic acetylcholine receptors: upregulation, age-related effects, and associations with drug use*. *15*(July 2015), 89–107. https://doi.org/10.1111/gbb.12251.Nicotinic

Merlugo, L., Santos, M. C., Sant'Anna, L. S., Cordeiro, E. W. F., Batista, L. A. C., Miotto, S. T. S., Garcia, C. V., Moreira, C. M., & Mendez, A. S. L. (2015). Alkaloids in erythrina by UPLC-ESI-MS and in vivo hypotensive potential of extractive preparations. *Evidence-Based Complementary and Alternative Medicine*, *2015*. https://doi.org/10.1155/2015/959081

Mineur, Y. S., Eibl, C., Young, G., Kochevar, C., Papke, R. L., Gundisch, D., & Picciotto, M. R. (2009). Cytisine-based nicotinic partial agonists as novel antidepressant compounds. *Journal of Pharmacology and Experimental Therapeutics*, *329*(1), 377–386. https://doi.org/10.1124/jpet.108.149609

Moroni, M., Zwart, R., Sher, E., Cassels, B. K., & Bermudez, I. (2006). α4β2 nicotinic receptors with high and low acetylcholine sensitivity: Pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. *Molecular Pharmacology*, *70*(2), 755–768. https://doi.org/10.1124/mol.106.023044

Muthukrishnan, S., Palanisamy, S., Subramanian, S., Selvaraj, S., Mari, K. R., & Kuppulingam, R. (2016). Phytochemical profile of *Erythrina variegata* by using High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectroscopy Analyses. *JAMS Journal of Acupuncture and Meridian Studies*, *9*(4), 207–212. https://doi.org/10.1016/j.jams.2016.06.001

Nagaraja, T. S., Mahmood, R., Krishna, V., Thippeswamy, B. S., & Veerapur, V. P. (2012). Evaluation of anxiolytic effect of *Erythrina mysorensis Gamb.* in mice. *Indian Journal of Pharmacology*, *44*(4), 489–492. https://doi.org/10.4103/0253-7613.99316

Nguyen, H. N., Rasmussen, B. A., & Perry, D. C. (2004). Binding and functional activity of nicotinic cholinergic receptors in selected rat brain regions are increased following long-term but not short-term nicotine treatment. *Journal of Neurochemistry*, *90*(1), 40–49. https://doi.org/10.1111/j.1471-4159.2004.02482.x

Nikoloutsou, I., Vasileiou, V., Litsiou, E., Kolokytha, S., Tsoutsa, A., & Zakynthinos, S. (2014). Smoking cessation changes basic metabolism , body weight , leptin and insulin levels , adipose tissue percentage , index of insulin resistance and index of insulin secretion. *Tobacco Induced Diseases*, *12*(Suppl 1), A24. https://doi.org/10.1186/1617-9625-12-S1-A24

O'Dell, L. E., Bruijnzeel, A. W., Smith, R. T., Parsons, L. H., Merves, M. L., Goldberger, B. A., Richardson, H. N., Koob, G. F., & Markou, A. (2006). Diminished nicotine withdrawal in adolescent rats: Implications for vulnerability to addiction. *Psychopharmacology*, *186*(4), 612–619. https://doi.org/10.1007/s00213-006-0383-6

Onusic, G. M., Nogueira, R. L., Pereira, A. M. S., Flausino, Júnior, O. A., & Viana, M. de B. (2003). Effects of chronic treatment with a water-alcohol extract from *Erythrina mulungu* on anxiety-related responses in rats. *Biological and Pharmaceutical Bulletin*, *26*(11), 1538–1542. https://doi.org/10.1248/bpb.26.1538

Overstreet, D. H., Knapp, D. J., & Breese, G. R. (2004). Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. *Pharmacology Biochemistry and Behavior*, *77*(2), 405–413. https://doi.org/10.1016/j.pbb.2003.11.010

Pajai, D. D., Paul, P., & Reche, A. (2023). Pharmacotherapy in tobacco cessation: A narrative review. *Cureus*, *15*(2). https://doi.org/10.7759/cureus.35086

Pandey, J., Murthy, S., Dubey, R., & Awasthi, D. (2021). Study of properties and applications nicotine alkaloids. *International Journal of Pharmacology and Pharmaceutical Sciences*, *3*(1), 01–04. https://doi.org/10.33545/26647206.2021.v3.i1a.9

Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. *Therapeutic Advances in Psychopharmacology*, *6*(2), 99–144. https://doi.org/10.1177/2045125316629071

Payne, L. (1991). The alkaloids of Erythrina: clonal evaluation and metabolic fate. 160. http://www.fao.org/ag/agp/agpc/doc/publicat/gutt-shel/x5556e0b.htm

Perez, X. A., Ly, J., Mcintosh, J. M., & Quik, M. (2012). Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbens. *342*(2), 335–344.

Petersen, I. N., Crestey, F., Jensen, A. A., Indurthi, D. C., Pedersen, H., Andreasen,

J. T., Balle, T., & Kristensen, J. L. (2015). Tying up nicotine: New selective competitive antagonist of the neuronal nicotinic acetylcholine receptors. *ACS Medicinal Chemistry Letters*, *6*(4), 472–475. https://doi.org/10.1021/acsmedchemlett.5b00028

Phukhatmuen, P., Meesakul, P., Suthiphasilp, V., Charoensup, R., Maneerat, T., Cheenpracha, S., Limtharakul, T., Pyne, S. G., & Laphookhieo, S. (2021). Antidiabetic and antimicrobial flavonoids from the twigs and roots of *Erythrina subumbrans* (Hassk.) Merr. *Heliyon*, *7*(4), e06904. https://doi.org/10.1016/j.heliyon.2021.e06904

Picciotto, M. R., & Mineur, Y. S. (2014). Molecules and circuits involved in nicotine addiction: The many faces of smoking. *Neuropharmacology*, *76 Pt B*(0 0), 545–553. https://doi.org/10.1016/j.neuropharm.2013.04.028

Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J. P. (1998). Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. *Nature*, *391*(6663), 173–177. https://doi.org/10.1038/34413

Pietilä, K., & Ahtee, L. (2000). Chronic nicotine administration in the drinking water affects the striatal dopamine in mice. *Pharmacology, Biochemistry, and Behavior*, *66*(1), 95–103. https://doi.org/10.1016/s0091-3057(00)00235-5

Pietilä, K., Lähde, T., Attila, M., Ahtee, L., & Nordberg, A. (1998). Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. *Naunyn-Schmiedeberg's Archives of Pharmacology*, *357*(2), 176–182. https://doi.org/10.1007/PL00005152

Pitchaiah, G., Viswanatha, G. L., Srinath, R., Nandakumar, K., Dayabaran, D., & Florance, E. J. (2010). Anxiolytic and anticonvulsant activity of aqueous extract of stem bark of Erythrina variegata in rodents. *International Journal of PharmTech Research*, *2*(1), 40–48.

Pitchaiah, G., Viswanatha, G., Srinath, R., & Nandakumar, K. (2008). Pharmacological evaluation of alcoholic extract of stem bark of *Erythrina Variegata* for anxiolytic and anticonvulsant activity in mice. *Pharmacologuonline*, *3*, 934–947.

Pithadia, A. (2009). *5-Hydroxytryptamine* receptor subtypes and their modulators with therapeutic potentials. *Journal of Clinical Medicine Research*, *1*(2), 72–80. https://doi.org/10.4021/jocmr2009.05.1237

Polak, T., & Jacob, C. C. (2022). Nicotine replacement therapy. *NeuroPsychopharmacotherapy*, *6*, 2569–2601. https://doi.org/10.1007/978-3-030-62059-2_398

Pomrenze, M. B., Fetterly, T. L., Winder, D. G., & Messing, R. O. (2017). The Corticotropin Releasing Factor Receptor 1 in alcohol use disorder: Still a valid drug target? *Alcoholism: Clinical and Experimental Research*, *41*(12), 1986–1999. https://doi.org/10.1111/acer.13507

Quick, M. W., & Lester, R. A. J. (2002). Desensitization of neuronal nicotinic receptors. *Journal of Neurobiology*, *53*(4), 457–478. https://doi.org/10.1002/neu.10109

Quiroz, G., Guerra-Díaz, N., Iturriaga-Vásquez, P., Rivera-Meza, M., Quintanilla, M. E., & Sotomayor-Zárate, R. (2018). *Erysodine,* a competitive antagonist at neuronal nicotinic acetylcholine receptors, decreases ethanol consumption in alcohol-preferring UChB rats. *Behavioural Brain Research*, *349*(1111), 169–176. https://doi.org/10.1016/j.bbr.2018.04.038

Rahman, S., Zhang, J., Engleman, E. A., & Corrigall, W. A. (2004). Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: A microdialysis study. *Neuroscience*, *129*, 415–424. https://doi.org/10.1016/j.neuroscience.2004.08.010

Raji, K., & Muthukumar, V. (2016a). Insilico evaluation of antismoking activity of erythrinine: A computational comparison against cytisine. *International Journal of Pharmacy and Pharmaceutical Sciences.* https://journals.innovareacademics.in/index.php/ijpps/article/view/9640/5475

Raji, K., & Muthukumar, V. (2016b). Insilico evaluation of antismoking activity of erythrinine: A computational comparison against cytisine. *International Journal of Pharmacy and Pharmaceutical Sciences*, *8*(2), 302–306.

Rambo, D. F., Biegelmeyer, R., Toson, N. S. B., Dresch, R. R., Moreno, P. R. H., & Henriques, A. T. (2019). The genus *Erythrina L.*: A review on its alkaloids, preclinical, and clinical studies. *Phytotherapy Research*, *33*(5), 1258–1276. https://doi.org/10.1002/ptr.6321

Ratnasooriya, W. D., & Dharmasiri, M. G. (1999). Aqueous extract of Sri Lankan Erythrina indica leaves has sedative but not analgesic activity. *Fitoterapia*, *70*(3), 311–313. https://doi.org/10.1016/S0367-326X(99)00027-1

Raupp, I. M., Sereniki, A., Virtuoso, S., Ghislandi, C., Cavalcanti e Silva, E. L., Trebien, H. A., Miguel, O. G., & Andreatini, R. (2008). Anxiolytic-like effect of chronic treatment with *Erythrina velutina* extract in the elevated plus-maze test. *Journal of Ethnopharmacology*, *118*(2), 295–299. https://doi.org/10.1016/j.jep.2008.04.016

Reavill, C., Walther, B., Stolerman, I. P., & Testa, B. (1990). Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. *Neuropharmacology*, *29*(7), 619–624. https://doi.org/10.1016/0028-3908(90)90022-J

Refojo, D., Schweizer, M., Kuehne, C., Ehrenberg, S., Thoeringer, C., Vogl, A. M., Dedic, N., Schumacher, M., Von Wolff, G., Avrabos, C., Touma, C., Engblom, D., Schütz, G., Nave, K. A., Eder, M., Wotjak, C. T., Sillaber, I., Holsboer, F., Wurst, W., & Deussing, J. M. (2011). Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. *Science*, *333*(6051), 1903–1907. https://doi.org/10.1126/science.1202107

Reid, M. S., Fox, L., Ho, L. B., & Berger, S. P. (2000). Nicotine stimulation of

extracellular glutamate levels in the nucleus accumbens: Neuropharmacological characterization. *Synapse*, *35*(2), 129–136. https://doi.org/10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D

Reperant, C., Pons, S., Dufour, E., Rollema, H., Gardier, A. M., & Maskos, U. (2010). Effect of the a 4 b 2 * nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in b 2 knock-out mice with selective re-expression of the b 2 subunit in the ventral tegmental area. *Neuropharmacology*, *58*, 346–350. https://doi.org/10.1016/j.neuropharm.2009.10.007

Ribeiro, M. D., Onusic, G. M., Poltronieri, S. C., & Viana, M. B. (2006). Effect of *Erythrina velutina* and *Erythrina mulungu* in rats submitted to animal models of anxiety and depression. *Brazilian Journal of Medical and Biological Research*, *39*(2), 263–270. https://doi.org/10.1590/S0100-879X2006000200013

Risdiana, N., Aulawi, K., & Sholikhah, E. N. (2025). Preclinical studies of anxiolytic and anti-depressant-like activities of *Erythrina sp.* plant extract: Systematic review and meta-analysis. *Journal of Pharmacy and Pharmacognosy Research*, *13*(4), 1045–1058. https://doi.org/10.56499/jppres24.2202_13.4.1045

Risdiana, N., Susilowati, R., Nurwening Sholikhah, E., & Partadiredja, G. (2022). The Effects of *Erythrina subumbrans* (Hassk.) Merr. Leaves Extract on Nicotine Withdrawal Syndrome and β2 nAChRs Expression in The Ventral Tegmental Area of Rats . *BIO Web of Conferences*, *49*, 01002. https://doi.org/10.1051/bioconf/20224901002

RJ, K., TE, M., LM, H., Lu, H., Yang, Y., & EA, S. (2019). Differential expression of nicotine withdrawal as a function of developmental age in the rat. *Pharmacology, Biochemistry, and Behavior*, *187*, 172802. https://doi.org/10.1016/j.pbb.2019.172802

Robinson, J. D., Chen, M., & Lerman, C. (2020). *Symptoms and Smoking Relapse*. *33*(2), 105–116. https://doi.org/10.1037/adb0000434.Evaluating

Roddy, E. (2004). Bupropion and other non-nicotine pharmacotherapies Using bupropion Pharmacokinetics and interactions. *British Medical Journal*, *328*, 509–511.

Roffman, J. L., Tanner, A. S., Eryilmaz, H., Rodriguez-Thompson, A., Silverstein, N. J., Ho, N. F., Nitenson, A. Z., Chonde, D. B., Greve, D. N., Abi-Dargham, A., Buckner, R. L., Manoach, D. S., Rosen, B. R., Hooker, J. M., & Catana, C. (2016). Dopamine D1 signaling organizes network dynamics underlying working memory. *Science Advances*, *2*(6). https://doi.org/10.1126/sciadv.1501672

Rohleder, N., & Kirschbaum, C. (2006). The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. *International Journal of Psychophysiology*, *59*(3), 236–243. https://doi.org/10.1016/j.ijpsycho.2005.10.012

Romanelli, M. N., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., & Gualtieri, F. (2007). Central nicotinic receptors: Structure, function, ligands, and therapeutic

potential. *ChemMedChem*, *2*(6), 746–767. https://doi.org/10.1002/cmdc.200600207

Rukachaisirikul, T., Innok, P., Aroonrerk, N., Boonamnuaylap, W., Limrangsun, S., Boonyon, C., Woonjina, U., & Suksamrarn, A. (2007). Antibacterial Pterocarpans from *Erythrina subumbrans*. *Journal of Ethnopharmacology*, *110*(1), 171–175. https://doi.org/10.1016/j.jep.2006.09.022

Rupprecht, L. E., Kreisler, A. D., Spierling, S. R., de Guglielmo, G., Kallupi, M., George, O., Donny, E. C., Zorrilla, E. P., & Sved, A. F. (2018). Self-administered nicotine increases fat metabolism and suppresses weight gain in male rats. *Psychopharmacology*, *235*(4), 1131–1140. https://doi.org/10.1007/s00213-018-4830-y

Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders. *Nature Reviews Neuroscience*, *14*(9), 609–625. https://doi.org/10.1038/nrn3381

Salgado, S., & Kaplitt, M. G. (2015). The nucleus accumbens: A comprehensive review. *Stereotactic and Functional Neurosurgery*, *93*(2), 75–93. https://doi.org/10.1159/000368279

Sallette, J., Pons, S., Devillers-Thiery, A., Soudant, M., De Carvalho, L. P., Changeux, J. P., & Corringer, P. J. (2005). Nicotine upregulates its own receptors through enhanced intracellular maturation. *Neuron*, *46*(4), 595–607. https://doi.org/10.1016/j.neuron.2005.03.029

Santhiya, N., Priyanga, S., Hemmalakshmi, S., & Devaki, K. (2016). Phytochemical analysis, anti inflammatory activity, in vitro antidiabetic activity and GC-MS profile of Erythrina variegata L. bark. *Journal of Applied Pharmaceutical Science*, *6*(7), 147–155. https://doi.org/10.7324/JAPS.2016.60722

Sarmiento, J., Zea, S., Saa, M., & Peñaherrera, E. (2018). *O investigation / research*. *1*(1), 1–14. https://revistabionatura.com/files/CS-2018.01.01.7---Revista-bionatura.pdf

Schultz, W. (2007). Multiple dopamine functions at different time courses. *Annual Review of Neuroscience*, *30*, 259–288. https://doi.org/10.1146/annurev.neuro.28.061604.135722

SD, G., BR, M., AM, B., RF, T., Sellers, E., & MI, D. (2005). Nicotine physical dependence and tolerance in the mouse following chronic oral administration. *Psychopharmacology*, *178*(2), 183–192. https://doi.org/10.1007/s00213-004-2007-3

Seibenhener, M. L., & Wooten, M. C. (2015). Use of the Open Field Maze to Measure Locomotor and Anxiety-like Behavior in Mice. *February*, 1–6. https://doi.org/10.3791/52434

Semba, J., & Wakuta, M. (2008). Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: Reversal by co-administration of bupropion.

Psychiatry and Clinical Neurosciences, *62*(4), 435–441. https://doi.org/10.1111/j.1440-1819.2008.01822.x

Seoane-collazo, P., Diéguez, C., Nogueiras, R., Rahmouni, K., Fernández-real, J. M., & López, M. (2021). Pharmacology & therapeutics nicotine ' actions on energy balance : Friend or foe ? *219*. https://doi.org/10.1016/j.pharmthera.2020.107693

Serafini, R. A., Pryce, K. D., & Zachariou, V. (2020). The mesolimbic dopamine system in chronic pain and associated affective comorbidities. *Biological Psychiatry*, *87*(1), 64–73. https://doi.org/10.1016/j.biopsych.2019.10.018

Serrano Cardona, L., & Muñoz Mata, E. (2013). Paraninfo Digital. Early Human Development, *83*(1), 1–11. https://doi.org/10.1016/j.earlhumdev.2006.05.022

Serrano, M. A. R., De Luca Batista, A. N., Da Silva Bolzani, V., De Ávila Santos, L., De Campos Nogueira, P. J., Nunes-De-Souza, R. L., Latif, A., & Arfan, M. (2011). Anxiolytic-like effects of erythrinian alkaloids from *Erythrina suberosa. Quimica Nova*, *34*(5), 808–811.

Seth, P., Cheeta, S., Tucci, S., & File, S. E. (2002). Nicotinic-serotonergic interactions in brain and behaviour. *Pharmacology Biochemistry and Behavior*, *71*(4), 795–805. https://doi.org/10.1016/S0091-3057(01)00715-8

Setti-Perdigão, P., Serrano, M. A. R., Flausino, O. A., Bolzani, V. S., Guimarães, M. Z. P., & Castro, N. G. (2013). *Erythrina mulungu* alkaloids are potent inhibitors of neuronal nicotinic receptor currents in mammalian cells. *PLoS ONE*, *8*(12), 8–13. https://doi.org/10.1371/journal.pone.0082726

Shiffman, S. M., & Jarvik, M. E. (1976). Smoking withdrawal symptoms in two weeks of abstinence. *Psychopharmacology*, *50*(1), 35–39. https://doi.org/10.1007/BF00634151

Simpson, S., Shankar, K., Kimbrough, A., & George, O. (2020). Role of corticotropin-releasing factor in alcohol and nicotine addiction. *Brain Research*, *1740*(November 2019), 146850. https://doi.org/10.1016/j.brainres.2020.146850

Soares-Cunha, C., de Vasconcelos, N. A. P., Coimbra, B., Domingues, A. V., Silva, J. M., Loureiro-Campos, E., Gaspar, R., Sotiropoulos, I., Sousa, N., & Rodrigues, A. J. (2020). Nucleus accumbens medium spiny neurons subtypes signal both reward and aversion. *Molecular Psychiatry*, *25*(12), 3241–3255. https://doi.org/10.1038/s41380-019-0484-3

Solomon, V. R., Tallapragada, V. J., Chebib, M., Johnston, G. A. R., & Hanrahan, J. R. (2019). GABA allosteric modulators : An overview of recent developments in non-benzodiazepine modulators. *European Journal of Medicinal Chemistry*, *171*, 434–461. https://doi.org/10.1016/j.ejmech.2019.03.043

Souza, M. S. D., & Markou, A. (2013). The "Stop" and "Go" of Nicotine Dependence: Role of GABA and Glutamate. *Cold Spring Harb Perspect Med*, 1–18. https://doi.org/https://doi.org/10.1101%2Fcshperspect.a012146

Speranza, L., Di Porzio, U., Viggiano, D., de Donato, A., & Volpicelli, F. (2021). Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. *Cells*, *10*(4). https://doi.org/10.3390/cells10040735

Spiess, J., Rivier, J., Rivier, C., & Vale, W. (1981). Primary structure of corticotropin-releasing factor from ovine hypothalamus. *Proceedings of the National Academy of Sciences of the United States of America*, *78*(10 I), 6517–6521. https://doi.org/10.1073/pnas.78.10.6517

Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004). A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. *The Primary Care Companion For CNS Disorders*, *6*(4). https://doi.org/10.4088/pcc.v06n0403

Stolerman, I. P., Chandler, C. J., Garcha, H. S., & Newton, J. M. (1997). Selective antagonism of behavioural effects of nicotine by *dihydro-β-erythroidine* in rats. *Psychopharmacology*, *129*(4), 390–397. https://doi.org/10.1007/s002130050205

Sun, Y., Duan, W., Meng, X., Li, H., & Jia, C. (2018). Varenicline is associated with a modest limitation in weight gain in smokers after smoking cessation: A meta-analysis. *Journal of Public Health (United Kingdom)*, *40*(2), e126–e132. https://doi.org/10.1093/pubmed/fdx056

Susilawati, E., Aligita, W., Kaniawati, M., Liani, D. A., Levita, J., Susilawati, Y., & Sumiwi, S. A. (2023). Effects of *Erythrina subumbrans* (Hassk.) Merr. leaves extract on RBCs membrane stability and egg white-induced edema in rats. *Journal of Applied Pharmaceutical Science*, *14*(01), 291–296. https://doi.org/10.7324/japs.2024.141692

Takahashi, H., Takada, Y., Urano, T., & Takada, A. (1998). Effects of nicotine and footshock stress on dopamine release in the striatum and nucleus accumbens. *45*(2), 157–162.

Takeda, K., Aotani, D., Kuga, Y., Jinno, T., Guo, T., Ogawa, K., Shimizu, Y., Hattori, R., Yagi, T., Koyama, H., Matsumura, S., Kataoka, H., & Tanaka, T. (2022). A mouse model of weight gain after nicotine withdrawal. *Biochemical and Biophysical Research Communications*, *588*, 140–146. https://doi.org/10.1016/j.bbrc.2021.12.064

Teixeira-Silva, F., Santos, F. N., Sarasqueta, D. F. O., Alves, M. F. S., Neto, V. A., De Paula, I. C. M., Estevam, C. D. S., Antoniolli, Â. R., & Marchioro, M. (2008). Benzodiazepine-like effects of the alcohol extract from Erythrina velutina leaves: Memory, anxiety, and epilepsy. *Pharmaceutical Biology*, *46*(5), 321–328. https://doi.org/10.1080/13880200801887658

Tiwari, R. K., Sharma, V., Pandey, R. K., & Shukla, S. S. (2020). Nicotine Addiction *: Neurobiology and Mechanism*. 1–7.

Tolu, S., Eddine, R., Marti, F., David, V., Graupner, M., Pons, S., Baudonnat, M., Husson, M., Besson, M., Reperant, C., Zemdegs, J., Pagès, C., Hay, Y. A. H.,

Lambolez, B., Caboche, J., Gutkin, B., Gardier, A. M., Changeux, J. P., Faure, P., & Maskos, U. (2013). Co-activation of VTA da and GABA neurons mediates nicotine reinforcement. *Molecular Psychiatry*, *18*(3), 382–393. https://doi.org/10.1038/mp.2012.83

Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hajek, P., Fagerström, K., Els, C., McRae, T., & Russ, C. (2020). Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. *Current Medical Research and Opinion*, *36*(5), 713–730. https://doi.org/10.1080/03007995.2020.1729708

Tonstad, S., Tønnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. *Jama*, *296*(1), 64–71. https://doi.org/10.1001/jama.296.1.64

Vasconcelos, S. M. M., Macedo, D. S., de Melo, C. T. V, Monteiro, A. P., Cunha, G. M. A., Sousa, F. C. F., Viana, G. S. B., Rodrigues, A. C. P., & Silveira, E. R. (2004). Central activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice. *Journal of Pharmacy and Pharmacology*, *56*(3), 389–393. https://doi.org/10.1211/0022357022746

VC, W., & Shoaib, M. (2007). Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. In *Psychopharmacology* (Vol. 195, Issue 3, pp. 303–313). https://doi.org/10.1007/s00213-007-0902-0

Vlachou, S., Guery, S., Froestl, W., Banerjee, D., Benedict, J., Finn, M. G., & Markou, A. (2011). Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. *Psychopharmacology*, *215*(1), 117–128. https://doi.org/10.1007/s00213-010-2119-x

Volkow, N. D., Fowler, J. S., Wang, G. J., & Goldstein, R. Z. (2002). Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. *Neurobiology of Learning and Memory*, *78*(3), 610–624. https://doi.org/10.1006/nlme.2002.4099

Volkow, N. D., Koob, G. F., & Mclellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *N Engl J Med*, *374*(4), 363–371. https://doi.org/10.1056/NEJMra1511480.Neurobiologic

Volkow, N. D., Michaelides, M., & Baler, R. (2019). The neuroscience of drug reward and addiction. *Physiological Reviews*, *99*(4), 2115–2140. https://doi.org/10.1152/physrev.00014.2018

Walf, A. A., & Frye, C. A. (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. *Nature Protocols*, *2*(2), 322–328. https://doi.org/10.1038/nprot.2007.44

Walker, N. B., Yan, Y., Tapia, M. A., Tucker, B. R., Thomas, L. N., George, B. E., West, A. M., Marotta, C. B., Lester, H. A., Dougherty, D. A., Holleran, K. M., Jones, S. R., & Drenan, R. M. (2023). *b 2 nAChR Activation on VTA DA Neurons Is Sufficient for Nicotine Reinforcement in Rats*. *10*(May).

Wang, H., & Sun, X. (2005). Desensitized nicotinic receptors in brain. *Brain Research Reviews*, *48*(3), 420–437. https://doi.org/10.1016/j.brainresrev.2004.09.003

Whiting, P. J., & Lindstrom, J. M. (1988). Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. *Journal of Neuroscience*, *8*(9), 3395–3404. https://doi.org/10.1523/jneurosci.08-09-03395.1988

Widiastuti, N. K., Virginia, N. M., Yastawan, I. M. F., Permatasari, A. A. A. P., Wiradana, P. A., Widhiantara, I. G., & Sucipto, T. H. (2023). Cytotoxicity evaluation of *Erythrina lithosperma* Miq. leaf extract against vero cell lines: *In vitro* study. *Research Journal of Pharmacy and Technology*, *16*(1), 153–158. https://doi.org/10.52711/0974-360X.2023.00028

Wills, L., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022). Neurobiological mechanisms of nicotine reward and aversion. *Pharmacological Reviews*, *74*(1), 271–310. https://doi.org/10.1124/PHARMREV.121.000299

Wise, R. A., & Robble, M. A. (2020). Dopamine and addiction. *Annual Review of Psychology*, *71*, 79–106.

Wittenberg, R. E., Wolfman, S. L., De Biasi, M., & Dani, J. A. (2021). Nicotinic acetylcholine receptors and nicotine addiction: A Brief Introduction. *Neuropharmacology*. https://doi.org/10.1016/j.neuropharm.2020.108256. Nicotinic

Wolfe, S. A., Sidhu, H., Patel, R. R., Kreifeldt, M., D'ambrosio, S. R., Contet, C., & Roberto, M. (2019). Molecular, morphological, and functional characterization of corticotropin-releasing factor receptor 1-expressing neurons in the central nucleus of the amygdala. *ENeuro*, *6*(3). https://doi.org/10.1523/ENEURO.0087-19.2019

Xi, Z. X., Spiller, K., & Gardner, E. L. (2009). Mechanism-based medication development for the treatment of nicotine dependence. *Acta Pharmacologica Sinica*, *30*(6), 723–739. https://doi.org/10.1038/aps.2009.46

Yashwant Kumar, A., Nandakumar, K., Handral, M., Talwar, S., & Dhayabaran, D. (2011). Hypoglycaemic and anti-diabetic activity of stem bark extracts *Erythrina indica* in normal and alloxan-induced diabetic rats. *Saudi Pharmaceutical Journal*, *19*(1), 35–42. https://doi.org/10.1016/j.jsps.2010.10.001

Yu, L. F., Zhang, H. K., Caldarone, B. J., Eaton, J. B., Lukas, R. J., & Kozikowski, A. P. (2014). Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors. *Journal of Medicinal Chemistry*, *57*(20), 8204–

8223. https://doi.org/10.1021/jm401937a

Yu, R., Tae, H. S., Xu, Q., Craik, D. J., Adams, D. J., Jiang, T., & Kaas, Q. (2019). Molecular dynamics simulations of *dihydro-β-erythroidine* bound to the human α4β2 nicotinic acetylcholine receptor. *British Journal of Pharmacology*, *176*(15), 2750–2763. https://doi.org/10.1111/bph.14698

Zambrano, C. A., Short, C. A., Salamander, R. M., Grady, S. R., & Marks, M. J. (2015). Density of a 4 b 2 * nAChR on the surface of neurons is modulated by chronic antagonist exposure. 1–14. https://doi.org/10.1002/prp2.111

Zhang, L., Dong, Y., Doyon, W. M., & Dani, J. A. (2012). Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. *71*(3), 184–191. https://doi.org/10.1016/j.biopsych.2011.07.024.

Zhao-Shea, R., Liu, L., Soll, L. G., Improgo, M. R., Meyers, E. E., McIntosh, J. M., Grady, S. R., Marks, M. J., Gardner, P. D., & Tapper, A. R. (2011). Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. *Neuropsychopharmacology*, *36*(5), 1021–1032. https://doi.org/10.1038/npp.2010.240

Zheng, F., Zheng, G., Deaciuc, A. G., Zhan, C. G., Dwoskin, L. P., & Crooks, P. A. (2009). Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the 4αβ27* nicotinic acetylcholine receptor. *Journal of Enzyme Inhibition and Medicinal Chemistry*, *24*(1), 157–168. https://doi.org/10.1080/14756360801945648

Zoli, M., Léna, C., Picciotto, M. R., & Changeux, J. P. (1998). Identification of four classes of brain nicotinic receptors using β mutant mice. *Journal of Neuroscience*, *18*(12), 4461–4472. https://doi.org/10.1523/jneurosci.18-12-04461.1998

Zorrilla, E. P., Logrip, M. L., & Koob, G. F. (2014). Corticotropin releasing factor: A key role in the neurobiology of addiction. *Frontiers in Neuroendocrinology*, *35*(2), 234–244. https://doi.org/10.1016/j.yfrne.2014.01.001.Corticotropin

Zorrilla, E. P., Valdez, G. R., & Weiss, F. (2001). Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. *Psychopharmacology*, *158*(4), 374–381. https://doi.org/10.1007/s002130100773